Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Alexza Pharmaceuticals Inc. | f58240exv32w1.htm |
| EX-21.1 - EX-21.1 - Alexza Pharmaceuticals Inc. | f58240exv21w1.htm |
| EX-31.2 - EX-31.2 - Alexza Pharmaceuticals Inc. | f58240exv31w2.htm |
| EX-31.1 - EX-31.1 - Alexza Pharmaceuticals Inc. | f58240exv31w1.htm |
| EX-10.45 - EX-10.45 - Alexza Pharmaceuticals Inc. | f58240exv10w45.htm |
| EX-10.47 - EX-10.47 - Alexza Pharmaceuticals Inc. | f58240exv10w47.htm |
| EX-10.46 - EX-10.46 - Alexza Pharmaceuticals Inc. | f58240exv10w46.htm |
| 10-K - FORM 10-K - Alexza Pharmaceuticals Inc. | f58240e10vk.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos.
333-132593, 333-141718, 333-149129, 333-157885, 333-162485, 333-164843, 333-151303, and 333-171604)
pertaining to the 2005 Equity Incentive Plan, 2005 Non-Employee Directors’ Stock Option Plan and
2005 Employee Stock Purchase Plan of Alexza Pharmaceuticals, Inc. and the Registration Statements
on Form S-3 (Nos. 333-161804, 333-162582, 333-166514, and 333-169649) and the related prospectuses
of Alexza Pharmaceuticals, Inc. of our reports dated March 15, 2011, with respect to the
consolidated financial statements of Alexza Pharmaceuticals, Inc. and the effectiveness of internal
control over financial reporting of Alexza Pharmaceuticals, Inc., included in this Annual Report
(Form 10-K) for the year ended December 31, 2010.
/s/ Ernst & Young LLP
Palo Alto, California
March 15, 2011
March 15, 2011